Â鶹ÊÓƵ

Aftersales and Chinese volumes point the way

Shares sold off despite strategic progress

The semiconductor company is stretching faith in the turnaround

The signs are that significant top-line growth will continue for this pharma and biotech technology company

The diversity of the group’s revenue streams mitigates sector-specific risk

The natural extracts manufacturer looks set to struggle this year as tariffs and high prices shrink profits

Property sales create headroom to cut debt

‘Significantly higher inflation’ leads to reset of medium-term goal

Volume declines highlight print market challenges

The legal platform looks well insulated from the tariff tumult